Find your next paid study

National Cancer Institute (NCI)NCT06406465

~$75 – $1,800

Actual pay is set by the research site.

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Background The development of new technologies now allow scientists to investigate the molecular basis and clinical manifestations of monoclonal B cell lympho…

Waldenstrom MacroglobulinemiaLymphoplasmacytic LymphomaMonoclonal B-Cell Lymphocytosis+2 more

National Heart, Lung, and Blood Institute (NHLBI)NCT00923507

~$10 – $675

Actual pay is set by the research site.

Phase 3

A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic…

Non-small Cell Lung Cancer

Merck Sharp & Dohme LLCNCT06345729

~$50 – $2,100

Actual pay is set by the research site.

Phase 2

A Phase II Study to Examine the Impact of CD22 CAR T-cells to Extend the Duration of Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Background: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from …

Acute Lymphoblastic LeukemiaB-All

National Cancer Institute (NCI)NCT07328503

~$75 – $1,800

Actual pay is set by the research site.

B-AllAcute Lymphoblastic Leukemia

Phase I Dose Escalation Study of Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-cell Acute Lymphoblastic Leukemia (B-ALL)

Background: B-cell acute lymphoblastic leukemia (B-ALL) is a type of blood cancer. Some people with B-ALL have a gene mutation that makes the disease hard to …

National Cancer Institute (NCI)NCT07572136

~$150 – $2,700

Actual pay is set by the research site.

Non Small Cell Lung Cancer

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN1)

This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.

Dizal PharmaceuticalsNCT06905197

Actual pay is set by the research site.

Urologic DiseasesMale Urogenital DiseasesPenile Diseases+3 more

Phase 1 Pilot Study of Bioengineered Penile Tissue Constructs in Subjects With Irreversibly Damaged Penile Corpora

The primary objective of this clinical trial is to evaluate the safety of autologous engineered corpora cavernosa + albuginea constructs for treatment of compl…

Wake Forest University Health SciencesNCT03463239

~$150 – $3,000

Actual pay is set by the research site.

Pancreatic Ductal AdenocarcinomaNon Small Cell Lung CancerColorectal Cancer+2 more

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors

This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

Verastem, Inc.NCT07020221

Actual pay is set by the research site.

Head & Neck Squamous Cell CarcinomaNon-Small Cell Lung CancerEsophageal Cancer+5 more

A Phase 1 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO 006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: * Part 1A is a dose escalation of STRO-006 monotherapy in se…

Sutro Biopharma, Inc.NCT07807345

Actual pay is set by the research site.

Phase 3

ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥ 50%.

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung …

Non-Small Cell Lung Cancer (NSCLC)

Bristol-Myers SquibbNCT07361510

~$50 – $2,250

Actual pay is set by the research site.

Observational

Effects of a Novel Perturbation Balance Training Program on Laboratory and Real-World Trip-Induced Losses of Balance and Falls Among Balance-Impaired Older Adults

The goal of this clinical trial is to learn if a novel balance training stepping exercise can reduce the risk of falling among adults over the age of 65. The m…

Accidental Fall

Virginia Polytechnic Institute and State UniversityNCT07891637

~$10 – $750

Actual pay is set by the research site.

Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive

A Phase 1b Study of Gilteritinib in Participants With Locally Advanced or Metastatic NSCLC With ALK Rearrangement After Prior Treatment With an ALK Inhibitor

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in…